Evidence map›Paper›PMID 33180981›Full record

ArticleChembiochem : a European journal of chemical biology2021

Simplified Monopalmitoyl Toll-like Receptor 2 Ligand Mini-UPam for Self-Adjuvanting Neoantigen-Based Synthetic Cancer Vaccines.

Thomas C van den Ende, Jeroen M M Heuts, Geoffroy P P Gential, Marten Visser, Michel J van de Graaff, Nataschja I Ho, Wim Jiskoot, A Rob P M Valentijn, Nico J Meeuwenoord, Herman S Overkleeft and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Thomas C van den EndeLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
Jeroen M M HeutsDepartment of Immunology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Geoffroy P P GentialLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
Marten VisserDepartment of Medical Oncology and Oncode Institute, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Michel J van de GraaffLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
Nataschja I HoDepartment of Immunology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Wim JiskootDivision of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
A Rob P M ValentijnClinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Nico J MeeuwenoordLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
Herman S OverkleeftLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
Jeroen D C CodéeLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
Sjoerd H van der BurgDepartment of Medical Oncology and Oncode Institute, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Els M E VerdegaalDepartment of Medical Oncology and Oncode Institute, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Gijsbert A van der MarelLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
Ferry OssendorpDepartment of Immunology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Dmitri V FilippovLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.ORCID 0000-0002-6978-7425
Leiden University · NLLeiden University Medical Center · NL

Funding

KWF Kankerbestrijding KWF-10815
6 · The paper itself

Abstract

Synthetic vaccines, based on antigenic peptides that comprise MHC-I and MHC-II T-cell epitopes expressed by tumors, show great promise for the immunotherapy of cancer. For optimal immunogenicity, the synthetic peptides (SPs) should be adjuvanted with suitable immunostimulatory additives. Previously, we have shown that improved immunogenicity in vivo is obtained with vaccine modalities in which an SP is covalently connected to an adjuvanting moiety, typically a ligand to Toll-like receptor 2 (TLR2). SPs were covalently attached to UPam, which is a derivative of the classic TLR2 ligand Pam

Indexed as

LigandsAntigens, NeoplasmCancer VaccinesCell LineDendritic CellsDrug DesignHumansInterleukin-8LipopeptidesLipoylationLymphocyte ActivationToll-Like Receptor 2Vaccines, SyntheticAntigens, NeoplasmCancer VaccinesInterleukin-8LigandsLipopeptidesToll-Like Receptor 2Vaccines, Syntheticcancer vaccinesdendritic cellslipopeptidesneoepitopessolid-phase synthesisTLR2 ligand

Identifiers

PMID33180981
PMCPMC8049070
OpenAlexW3106443667

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.